Glycopyrrolate Oral Solution
Brand Names: Glycopyrrolate Oral Solution Generic
Methodology & AI Transparency ⓘ
Glycopyrrolate Oral Solution Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy)
- 2 Real-world patient consensus: Tracked across 17 patient dosage logs with a 90% satisfaction benchmark (RxCUI 999961).
- 3 Typical cash cost range: Public pharmacy ledger: $15.34 low cash benchmark vs. $37.58 chain retail average ($0.1689/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Glycopyrrolate Oral Solution tolerability events: constipation (8.1%), vomiting (3.6%), dry mouth (7%).
Ask our AI Specialists anything about Glycopyrrolate Oral Solution
Glycopyrrolate Oral Solution Mechanism, CYP450 Pathways & DailyMed Monograph
Glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy)
12.1 Mechanism of Action Glycopyrrolate is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of salivation by preventing the stimulation of these receptors.
Clinical clearance of Glycopyrrolate Oral Solution (Anticholinergic) relies on mixed metabolic conjugation and unchanged urinary excretion across glycopyrrolate oral solution regimens with a Terminal t½ estimated at 4–14 hrs depending on renal/hepatic reserve (Glycopyrrolate Oral Solution) half-life; patients absorbing at ~3% systemic bioavailability (Glycopyrrolate Oral Solution) bioavailability typically observe target onset around time to peak concentration spans 1 to 2 hrs under glycopyrrolate oral solution maintenance.
FDA clinical labeling for Glycopyrrolate Oral Solution restricts administration in documented intolerance or hypersensitivity reaction involving glycopyrrolate oral solution (anticholinergic); concurrent restricted medications flagged in section 4/7 of the glycopyrrolate oral solution dailymed monograph (999961) across 1 mg/5mL Liquid, 0.02 mg, with self-reported patient tracking dominated by nausea (8.4% of reports), headache (8.1% of reports), constipation (8.1% of reports).
Check serum potassium and creatinine periodically if Glycopyrrolate Oral Solution is co-administered with potassium-retaining agents.
Intestinal or renal P-glycoprotein competition with Glycopyrrolate Oral Solution can increase systemic glycoside exposure.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Glycopyrrolate Oral Solution (anticholinergic)
- Concurrent restricted medications flagged in Section 4/7 of the Glycopyrrolate Oral Solution DailyMed monograph (999961)
Logged Side-Effect Incidence (17 Reports)
Glycopyrrolate Oral Solution Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glycopyrrolate Oral Solution)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and: What a 8,509-Participant Study Found BGF triple therapy improved symptoms and HRQoL vs dual therapies over 24 and 52 weeks in patients with moderate-to-very severe COPD. Respiratory medicine • 2021-01-15 • Phase III Randomized Trial | N = 8,509 | 96/100 | PMID 34171789 ↗ |
| Can This Approach Help? Inside the Latest Research on Glycopyrrolate/Formoterol (Bevespi) on Ventilation and Gas Exchange Abnormalities The purpose of this study is to determine whether the new inhaler, Bevespi improves lung function. Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, that can provide useful images of the functioning of the lung will b ClinicalTrials.gov Registry (NIH NLM) • 2019-11-12 • Completed Human Clinical Trial (NCT) | N = 20 | 89/100 | PMID NCT03324607 ↗ |
| Can This Approach Help? Inside the Latest Research on Frequent productive cough in COPD relates to exacerbation risk and treatment Among participants without an exacerbation history in the prior 12 months, FPC identified those at higher exacerbation risk. Respiratory medicine • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41237914 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of glycopyrrolate/formoterol fumarate metered dose inhaler GFF MDI improved lung function versus monocomponents and placebo MDI in the Japan subpopulation of PINNACLE-4. Respiratory investigation • 2021-01-15 • Phase III Randomized Trial | N = 150 | 88/100 | PMID 32917556 ↗ |
Glycopyrrolate Oral Solution Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1689/unit (~$5.07/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $37.58 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $15.34 / mo | View logs ↓ |
Glycopyrrolate Oral Solution Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Glycopyrrolate Oral Solution RxNorm Concept ID | 999961 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1689 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $37.58 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.34 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Glycopyrrolate Oral Solution Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Glycopyrrolate Oral Solution integrating DailyMed SPL (2026-04-02), CMS NADAC ($0.1689/unit), and 17 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Glycopyrrolate Oral Solution community threads and patient logs by age, biological sex, dosage, and treatment duration.